Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decline in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) was the target of a significant decline in short interest in September. As of September 15th, there was short interest totaling 6,607 shares, a decline of 50.9% from the August 31st total of 13,469 shares. Based on an average daily volume of 43,279 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.6% of the shares of the company are short sold.

Regentis Biomaterials Stock Performance

RGNT traded down $0.04 on Tuesday, reaching $1.85. The company had a trading volume of 58,605 shares, compared to its average volume of 1,869,644. Regentis Biomaterials has a one year low of $1.23 and a one year high of $15.50. The company has a fifty day moving average of $1.97 and a 200-day moving average of $2.63.

Get Regentis Biomaterials alerts:

Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last posted its quarterly earnings data on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent SEC filing.

About Regentis Biomaterials

(Get Free Report)

Regentis Biomaterials Ltd. is an Israel-based medical device company developing biomaterial technologies for the treatment of cartilage injuries and other orthopedic conditions. The company focuses on regenerative solutions intended to support the repair of damaged tissue while reducing the need for more invasive procedures.

Its lead product is GelrinC, a synthetic, cell-free hydrogel implant designed for the treatment of focal cartilage defects in the knee. The product is placed arthroscopically and forms a scaffold intended to integrate with surrounding tissue and support the regeneration of hyaline-like cartilage.

Regentis Biomaterials operates as a clinical-stage company, with activities centered on product development, clinical evaluation, regulatory advancement and potential commercialization of its orthopedic biomaterial platform.

See Also

• Five stocks we like better than Regentis Biomaterials
• CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
• CoreWeave Comes With Risks: Analysts Split on What Matters Most
• Bottlenecking the Future: TSMC Prices Out the Competition
• Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?

Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.